{
  "topic_id": "mpx1016",
  "ingest_source": "gold",
  "candidates": [
    {
      "nct_id": "NCT06196424",
      "title": "A Study to Investigate the Family History of Cancer in Patients With Non-small Cell Lung Cancer (FAHIC - Lung).",
      "brief_title": "A Study to Investigate the Family History of Cancer in Patients With Non-small Cell Lung Cancer (FAHIC - Lung).",
      "status": "RECRUITING",
      "phase": [],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        "study questionnaire to investigate family history"
      ],
      "sponsor": "Fondazione Policlinico Universitario Campus Bio-Medico",
      "enrollment": 180,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='never smoker'",
        "cond='non-small cell lung cancer', kw='RET fusion'",
        "cond='non-small cell lung cancer', kw='ALK fusion'",
        "cond='non-small cell lung cancer', kw='non-smoker'"
      ]
    },
    {
      "nct_id": "NCT06074588",
      "title": "Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)",
      "brief_title": "Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)",
      "status": "RECRUITING",
      "phase": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        "Sacituzumab tirumotecan",
        "Docetaxel",
        "Pemetrexed"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "enrollment": 556,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK rearrangement'",
        "cond='non-small cell lung cancer', kw='RET fusion'",
        "cond='non-small cell lung cancer', kw='ALK fusion'"
      ]
    },
    {
      "nct_id": "NCT00301119",
      "title": "Lung Cancer Biomarkers and Screening",
      "brief_title": "Lung Cancer Biomarkers and Screening",
      "status": "RECRUITING",
      "phase": [],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [],
      "sponsor": "NYU Langone Health",
      "enrollment": 10850,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='never smoker'",
        "cond='non-small cell lung cancer', kw='non-smoker'"
      ]
    },
    {
      "nct_id": "NCT03093116",
      "title": "A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements",
      "brief_title": "A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements",
      "status": "RECRUITING",
      "phase": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Solid Tumors",
        "Metastatic Solid Tumors"
      ],
      "interventions": [
        "Oral repotrectinib (TPX-0005)"
      ],
      "sponsor": "Turning Point Therapeutics, Inc.",
      "enrollment": 500,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK rearrangement'",
        "cond='non-small cell lung cancer', kw='ROS1 rearrangement'"
      ]
    },
    {
      "nct_id": "NCT03786692",
      "title": "Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC",
      "brief_title": "Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Carcinoma of Lung, TNM Stage 4"
      ],
      "interventions": [
        "Arm A",
        "Arm B"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "enrollment": 117,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='never smoker'",
        "cond='non-small cell lung cancer', kw='non-smoker'"
      ]
    },
    {
      "nct_id": "NCT04084717",
      "title": "Study of Crizotinib for ROS1 and MET Activated Lung Cancer",
      "brief_title": "Study of Crizotinib for ROS1 and MET Activated Lung Cancer",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Non-squamous Non-small-cell Lung Cancer",
        "Stage IV Non-small Cell Lung Cancer",
        "ROS1 Gene Rearrangement"
      ],
      "interventions": [
        "Crizotinib"
      ],
      "sponsor": "University Health Network, Toronto",
      "enrollment": 50,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK rearrangement'",
        "cond='non-small cell lung cancer', kw='ROS1 rearrangement'"
      ]
    },
    {
      "nct_id": "NCT04322890",
      "title": "Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation",
      "brief_title": "Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "EGFR Gene Mutation",
        "ALK Gene Mutation"
      ],
      "interventions": [
        "Osimertinib",
        "Alectinib 150 MG",
        "Crizotinib 250 MG",
        "Savolitinib, Crizotinib."
      ],
      "sponsor": "Hunan Province Tumor Hospital",
      "enrollment": 6000,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='RET fusion'",
        "cond='non-small cell lung cancer', kw='ALK fusion'"
      ]
    },
    {
      "nct_id": "NCT04777175",
      "title": "A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer",
      "brief_title": "A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer",
      "status": "RECRUITING",
      "phase": [],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        "immunity therapy"
      ],
      "sponsor": "Yongchang Zhang",
      "enrollment": 186,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='RET fusion'",
        "cond='non-small cell lung cancer', kw='ALK fusion'"
      ]
    },
    {
      "nct_id": "NCT04900935",
      "title": "Patient-centered, Optimal Integration of Survivorship and Palliative Care",
      "brief_title": "Patient-centered, Optimal Integration of Survivorship and Palliative Care",
      "status": "RECRUITING",
      "phase": [
        "NA"
      ],
      "conditions": [
        "Stage IV Non-small Cell Lung Cancer",
        "Targeted Therapy",
        "Nonsmall Cell Lung Cancer"
      ],
      "interventions": [
        "POISE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "enrollment": 70,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='RET fusion'",
        "cond='non-small cell lung cancer', kw='ALK fusion'"
      ]
    },
    {
      "nct_id": "NCT05014464",
      "title": "ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma",
      "brief_title": "ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        "Crizotinib"
      ],
      "sponsor": "Hunan Province Tumor Hospital",
      "enrollment": 90,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK rearrangement'",
        "cond='non-small cell lung cancer', kw='ALK fusion'"
      ]
    },
    {
      "nct_id": "NCT05122806",
      "title": "Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC",
      "brief_title": "Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC",
      "status": "RECRUITING",
      "phase": [
        "NA"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "ALK Gene Rearrangement Positive"
      ],
      "interventions": [
        "RNAseq"
      ],
      "sponsor": "Groupe Francais De Pneumo-Cancerologie",
      "enrollment": 100,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK rearrangement'",
        "cond='non-small cell lung cancer', kw='ALK fusion'"
      ]
    },
    {
      "nct_id": "NCT05456256",
      "title": "A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma",
      "brief_title": "A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of Lung",
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        "LP-300",
        "Pemetrexed",
        "Carboplatin"
      ],
      "sponsor": "Lantern Pharma Inc.",
      "enrollment": 90,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='never smoker'",
        "cond='non-small cell lung cancer', kw='non-smoker'"
      ]
    },
    {
      "nct_id": "NCT06563999",
      "title": "Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.",
      "brief_title": "Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer Stage III",
        "Mutation"
      ],
      "interventions": [
        "Sunvozertinib",
        "Crizotinib",
        "Pralsetinib",
        "Larotrectinib"
      ],
      "sponsor": "Sun Yat-sen University",
      "enrollment": 120,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='RET fusion'",
        "cond='non-small cell lung cancer', kw='ALK fusion'"
      ]
    },
    {
      "nct_id": "NCT06800586",
      "title": "Tumors and Respiratory System Diseases Due to Air Pollution: New Biomarkers of Exposure and Effects",
      "brief_title": "Tumors and Respiratory System Diseases Due to Air Pollution: New Biomarkers of Exposure and Effects",
      "status": "RECRUITING",
      "phase": [],
      "conditions": [
        "COPD",
        "Lung Cancer (NSCLC)",
        "Leukemia"
      ],
      "interventions": [],
      "sponsor": "IRCCS Azienda Ospedaliero-Universitaria di Bologna",
      "enrollment": 300,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='never smoker'",
        "cond='non-small cell lung cancer', kw='non-smoker'"
      ]
    },
    {
      "nct_id": "NCT07330596",
      "title": "QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC",
      "brief_title": "QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "NSCLC (Advanced Non-small Cell Lung Cancer)"
      ],
      "interventions": [
        "QL1706 combined with Chemotherapy",
        "Chemotherapy"
      ],
      "sponsor": "Anhui Provincial Cancer Hospital",
      "enrollment": 96,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='RET fusion'",
        "cond='non-small cell lung cancer', kw='ALK fusion'"
      ]
    },
    {
      "nct_id": "NCT01639508",
      "title": "Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity",
      "brief_title": "Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        "Cabozantinib"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "enrollment": 86,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='RET fusion'"
      ]
    },
    {
      "nct_id": "NCT01717924",
      "title": "Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma",
      "brief_title": "Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma",
      "status": "RECRUITING",
      "phase": [
        "NA"
      ],
      "conditions": [
        "Signet Ring Cell Gastric Adenocarcinoma"
      ],
      "interventions": [
        "peri-operative chemotherapy",
        "Surgery first"
      ],
      "sponsor": "University Hospital, Lille",
      "enrollment": 314,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='Adenocarcinoma', kw='signet-ring'"
      ]
    },
    {
      "nct_id": "NCT01994057",
      "title": "A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment",
      "brief_title": "A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment",
      "status": "RECRUITING",
      "phase": [],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)",
        "EGFR-TKI Resistant Mutation",
        "EGFR-TKI Sensitizing Mutation"
      ],
      "interventions": [],
      "sponsor": "Sun Yat-sen University",
      "enrollment": 1000,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK fusion'"
      ]
    },
    {
      "nct_id": "NCT03199651",
      "title": "Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer",
      "brief_title": "Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer",
      "status": "RECRUITING",
      "phase": [
        "NA"
      ],
      "conditions": [
        "Cigarette Smoker",
        "Current Smoker",
        "Lung Adenocarcinoma"
      ],
      "interventions": [
        "Best Practice",
        "Biospecimen Collection",
        "Biospecimen Collection",
        "Laboratory Biomarker Analysis"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "enrollment": 3584,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='non-smoker'"
      ]
    },
    {
      "nct_id": "NCT03774758",
      "title": "Biomarkers for Risk Stratification in Lung Cancer",
      "brief_title": "Biomarkers for Risk Stratification in Lung Cancer",
      "status": "RECRUITING",
      "phase": [],
      "conditions": [
        "Nodule Solitary Pulmonary",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        "Guardant Health ct-DNA LUNAR assay"
      ],
      "sponsor": "University of California, San Francisco",
      "enrollment": 590,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='non-smoker'"
      ]
    },
    {
      "nct_id": "NCT04087473",
      "title": "Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC",
      "brief_title": "Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC",
      "status": "RECRUITING",
      "phase": [],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "ALK-Positive Lung Cancer"
      ],
      "interventions": [],
      "sponsor": "National Cancer Centre, Singapore",
      "enrollment": 50,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK fusion'"
      ]
    },
    {
      "nct_id": "NCT04302025",
      "title": "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)",
      "brief_title": "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        "Alectinib",
        "Entrectinib",
        "Vemurafenib",
        "Cobimetinib"
      ],
      "sponsor": "Genentech, Inc.",
      "enrollment": 99,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT04701476",
      "title": "TATE and Pembrolizumab (MK3475) in mCRC and NSCLC",
      "brief_title": "TATE and Pembrolizumab (MK3475) in mCRC and NSCLC",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer; Lung Cancer"
      ],
      "interventions": [
        "TATE and pembrolizumab",
        "TAS-102 pill",
        "Regorafenib Pill"
      ],
      "sponsor": "Teclison Ltd.",
      "enrollment": 110,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT04716257",
      "title": "A Prospective, Multi-center, Real-world Study of Ovarian Metastatic Colorectal Cancer Patients",
      "brief_title": "A Prospective, Multi-center, Real-world Study of Ovarian Metastatic Colorectal Cancer Patients",
      "status": "RECRUITING",
      "phase": [],
      "conditions": [
        "Ovarian Metastasis",
        "Colorectal Cancer"
      ],
      "interventions": [],
      "sponsor": "West China Hospital",
      "enrollment": 400,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='Adenocarcinoma', kw='signet-ring'"
      ]
    },
    {
      "nct_id": "NCT04777084",
      "title": "The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.",
      "brief_title": "The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        "IBI318"
      ],
      "sponsor": "Hunan Province Tumor Hospital",
      "enrollment": 120,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK fusion'"
      ]
    },
    {
      "nct_id": "NCT05098132",
      "title": "Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers",
      "brief_title": "Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers",
      "status": "RECRUITING",
      "phase": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Non Small Cell Lung Cancer",
        "Untreated Advanced NSCLC"
      ],
      "interventions": [
        "STK-012",
        "pembrolizumab",
        "pemetrexed",
        "carboplatin"
      ],
      "sponsor": "Synthekine",
      "enrollment": 364,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT05229614",
      "title": "Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease",
      "brief_title": "Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Melanoma"
      ],
      "interventions": [
        "Carbon Ion Therapy",
        "Immunotherapy (Pembrolizumab)"
      ],
      "sponsor": "CNAO National Center of Oncological Hadrontherapy",
      "enrollment": 27,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT05236946",
      "title": "Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT",
      "brief_title": "Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT",
      "status": "RECRUITING",
      "phase": [
        "PHASE3"
      ],
      "conditions": [
        "Asymptomatic Brain Metastases",
        "Driver Mutation Positive Non-small Cell Lung Cancer"
      ],
      "interventions": [
        "Stereotactic radiosurgery/whole brain radiotherapy",
        "Tyrosine kinase inhibitor"
      ],
      "sponsor": "Tata Memorial Hospital",
      "enrollment": 190,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK rearrangement'"
      ]
    },
    {
      "nct_id": "NCT05241028",
      "title": "Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer",
      "brief_title": "Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        "Ensartinib"
      ],
      "sponsor": "Hebei Medical University Fourth Hospital",
      "enrollment": 80,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK fusion'"
      ]
    },
    {
      "nct_id": "NCT05276726",
      "title": "A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1",
      "brief_title": "A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1",
      "status": "RECRUITING",
      "phase": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        "JAB 21822"
      ],
      "sponsor": "Allist Pharmaceuticals, Inc.",
      "enrollment": 104,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT05284539",
      "title": "Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer",
      "brief_title": "Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        "Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab"
      ],
      "sponsor": "Hunan Province Tumor Hospital",
      "enrollment": 760,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK fusion'"
      ]
    },
    {
      "nct_id": "NCT05487391",
      "title": "A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.",
      "brief_title": "A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.",
      "status": "RECRUITING",
      "phase": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        "QL1706 injection",
        "Vinorelbine Tartrate",
        "Paclitaxel",
        "Cisplatin"
      ],
      "sponsor": "Qilu Pharmaceutical Co., Ltd.",
      "enrollment": 632,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK fusion'"
      ]
    },
    {
      "nct_id": "NCT05522660",
      "title": "Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer",
      "brief_title": "Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer",
      "status": "RECRUITING",
      "phase": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Melanoma"
      ],
      "interventions": [
        "Stereotactic radiosurgery",
        "Immune checkpoint inhibitor"
      ],
      "sponsor": "ETOP IBCSG Partners Foundation",
      "enrollment": 180,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT05602259",
      "title": "PROspective Trial on EOsinophilia in Non-Small Cell Lung Cancer (NSCLC).",
      "brief_title": "PROspective Trial on EOsinophilia in Non-Small Cell Lung Cancer (NSCLC).",
      "status": "RECRUITING",
      "phase": [
        "NA"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        "induced sputum",
        "lung biopsy",
        "bronchoalveolar lavage",
        "blood draw"
      ],
      "sponsor": "Centre Hospitalier Universitaire de Liege",
      "enrollment": 200,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT05724004",
      "title": "Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)",
      "brief_title": "Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)",
      "status": "RECRUITING",
      "phase": [
        "NA"
      ],
      "conditions": [
        "Radiotherapy Side Effect",
        "Non-small Cell Lung Cancer",
        "ALK Gene Mutation"
      ],
      "interventions": [
        "SBRT/SRS/radiation therapy"
      ],
      "sponsor": "Karolinska University Hospital",
      "enrollment": 70,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK rearrangement'"
      ]
    },
    {
      "nct_id": "NCT05742607",
      "title": "IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)",
      "brief_title": "IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        "IPH5201 + durvalumab + standard chemotherapy"
      ],
      "sponsor": "Innate Pharma",
      "enrollment": 70,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT05789082",
      "title": "A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation",
      "brief_title": "A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation",
      "status": "RECRUITING",
      "phase": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        "Divarasib",
        "Pembrolizumab",
        "Carboplatin",
        "Cisplatin"
      ],
      "sponsor": "Hoffmann-La Roche",
      "enrollment": 320,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT05950139",
      "title": "Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC",
      "brief_title": "Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC",
      "status": "RECRUITING",
      "phase": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "NSCLC Stage IV",
        "ALK Fusion Protein Expression"
      ],
      "interventions": [
        "Peptide vaccine"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "enrollment": 12,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK fusion'"
      ]
    },
    {
      "nct_id": "NCT05973773",
      "title": "REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)",
      "brief_title": "REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)",
      "status": "RECRUITING",
      "phase": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation"
      ],
      "interventions": [
        "TAS6417"
      ],
      "sponsor": "Taiho Oncology, Inc.",
      "enrollment": 272,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT06031558",
      "title": "Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC",
      "brief_title": "Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC",
      "status": "RECRUITING",
      "phase": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        "SY-5007"
      ],
      "sponsor": "Shouyao Holdings (Beijing) Co. LTD",
      "enrollment": 120,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='RET fusion'"
      ]
    },
    {
      "nct_id": "NCT06068049",
      "title": "OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain",
      "brief_title": "OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain",
      "status": "RECRUITING",
      "phase": [],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [],
      "sponsor": "AstraZeneca",
      "enrollment": 500,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='non-smoker'"
      ]
    },
    {
      "nct_id": "NCT06092086",
      "title": "Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC",
      "brief_title": "Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "ALK Positive Non-small Cell Lung Cancer"
      ],
      "interventions": [
        "Loratinib"
      ],
      "sponsor": "Guangdong Association of Clinical Trials",
      "enrollment": 126,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK rearrangement'"
      ]
    },
    {
      "nct_id": "NCT06109558",
      "title": "The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC",
      "brief_title": "The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC",
      "status": "RECRUITING",
      "phase": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "RET Gene Mutation",
        "MET Amplification"
      ],
      "interventions": [
        "LMV-12(HE003)"
      ],
      "sponsor": "Hunan Province Tumor Hospital",
      "enrollment": 120,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='RET fusion'"
      ]
    },
    {
      "nct_id": "NCT06147570",
      "title": "A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer",
      "brief_title": "A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Nonsmall Cell Lung Cancer"
      ],
      "interventions": [
        "HS-10365 capsules"
      ],
      "sponsor": "Jiangsu Hansoh Pharmaceutical Co., Ltd.",
      "enrollment": 62,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='RET fusion'"
      ]
    },
    {
      "nct_id": "NCT06156527",
      "title": "A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker",
      "brief_title": "A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Lazertinib"
      ],
      "interventions": [
        "Lazertinib",
        "Bevacizumab Injectable Product"
      ],
      "sponsor": "National Cancer Center, Korea",
      "enrollment": 120,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='non-smoker'"
      ]
    },
    {
      "nct_id": "NCT06234579",
      "title": "Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)",
      "brief_title": "Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)",
      "status": "RECRUITING",
      "phase": [],
      "conditions": [
        "ALK Gene Mutation",
        "NSCLC Stage IV",
        "ALK Sensitizing Mutation"
      ],
      "interventions": [
        "Biopsy (tissue or liquid)"
      ],
      "sponsor": "Fondazione Policlinico Universitario Agostino Gemelli IRCCS",
      "enrollment": 108,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK rearrangement'"
      ]
    },
    {
      "nct_id": "NCT06248606",
      "title": "Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases",
      "brief_title": "Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "NSCLC",
        "KRAS G12C"
      ],
      "interventions": [
        "Adagrasib",
        "Stereotactic Radiosurgery"
      ],
      "sponsor": "Ryan Gentzler, MD",
      "enrollment": 30,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT06315010",
      "title": "REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis",
      "brief_title": "REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "NSCLC",
        "Brain Metastases",
        "ROS1 Gene Rearrangement"
      ],
      "interventions": [
        "Repotrectinib"
      ],
      "sponsor": "MedSIR",
      "enrollment": 20,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ROS1 rearrangement'"
      ]
    },
    {
      "nct_id": "NCT06361589",
      "title": "Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients",
      "brief_title": "Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients",
      "status": "RECRUITING",
      "phase": [],
      "conditions": [
        "ALK-positive Non-small Cell Lung Cancer",
        "Real World Study"
      ],
      "interventions": [
        "Lorlatinib"
      ],
      "sponsor": "Sichuan Cancer Hospital and Research Institute",
      "enrollment": 200,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK fusion'"
      ]
    },
    {
      "nct_id": "NCT06501378",
      "title": "Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis",
      "brief_title": "Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "NSCLC Stage IV"
      ],
      "interventions": [
        "PD-1/PD-L1 inhibitor plus chemotherapy",
        "SRT/WBRT"
      ],
      "sponsor": "Fudan University",
      "enrollment": 40,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT06528847",
      "title": "Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma",
      "brief_title": "Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        "Benmelstobart"
      ],
      "sponsor": "Shanghai Pulmonary Hospital, Shanghai, China",
      "enrollment": 62,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK rearrangement'"
      ]
    },
    {
      "nct_id": "NCT06581419",
      "title": "A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors",
      "brief_title": "A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors",
      "status": "RECRUITING",
      "phase": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Neoplasm",
        "Advanced or Metastatic Non-small Cell Lung Cancer"
      ],
      "interventions": [
        "IAP0971"
      ],
      "sponsor": "SUNHO（China）BioPharmaceutical CO., Ltd.",
      "enrollment": 78,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT06620835",
      "title": "Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib",
      "brief_title": "Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "NSCLC"
      ],
      "interventions": [
        "Blood samples for Hematology",
        "Blood samples for Chemistry",
        "Blood sample for liver function tests",
        "Pregnancy test"
      ],
      "sponsor": "Groupe Francais De Pneumo-Cancerologie",
      "enrollment": 45,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK rearrangement'"
      ]
    },
    {
      "nct_id": "NCT06735391",
      "title": "A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations",
      "brief_title": "A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations",
      "status": "RECRUITING",
      "phase": [
        "PHASE3"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Non-squamous NSCLC",
        "Harboring EGFR Sensitive Mutations NSCLC",
        "Previously Untreated Systematically NSCLC"
      ],
      "interventions": [
        "JMT101",
        "Osimertinib"
      ],
      "sponsor": "Shanghai JMT-Bio Inc.",
      "enrollment": 516,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT06875310",
      "title": "A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)",
      "brief_title": "A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)",
      "status": "RECRUITING",
      "phase": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        "Adagrasib",
        "Pembrolizumab",
        "Carboplatin",
        "Pemetrexed"
      ],
      "sponsor": "Mirati Therapeutics Inc.",
      "enrollment": 630,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT06939595",
      "title": "A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer",
      "brief_title": "A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer",
      "status": "RECRUITING",
      "phase": [
        "PHASE3"
      ],
      "conditions": [
        "Non Squamous Non Small Cell Lung Cancer"
      ],
      "interventions": [
        "CT-P51",
        "EU-approved Keytruda"
      ],
      "sponsor": "Celltrion",
      "enrollment": 606,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT06946797",
      "title": "A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)",
      "brief_title": "A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        "Nivolumab",
        "Ipilimumab",
        "Carboplatin",
        "Paclitaxel"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "enrollment": 76,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT07020221",
      "title": "A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors",
      "brief_title": "A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors",
      "status": "RECRUITING",
      "phase": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma",
        "Non Small Cell Lung Cancer",
        "Colorectal Cancer"
      ],
      "interventions": [
        "VS-7375",
        "Cetuximab",
        "Carboplatin + Pemetrexed + Pembrolizumab",
        "Gemcitabine"
      ],
      "sponsor": "Verastem, Inc.",
      "enrollment": 295,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT07099027",
      "title": "The Lung Health Check Pilot",
      "brief_title": "The Lung Health Check Pilot",
      "status": "RECRUITING",
      "phase": [
        "NA"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        "Low dose CT"
      ],
      "sponsor": "Royal College of Surgeons, Ireland",
      "enrollment": 2183,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='non-smoker'"
      ]
    },
    {
      "nct_id": "NCT07140016",
      "title": "A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)",
      "brief_title": "A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)",
      "status": "RECRUITING",
      "phase": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)",
        "Anaplastic Lymphoma Kinase (ALK) Positive"
      ],
      "interventions": [
        "gilteritinib"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "enrollment": 40,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='ALK rearrangement'"
      ]
    },
    {
      "nct_id": "NCT07161310",
      "title": "Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors",
      "brief_title": "Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors",
      "status": "RECRUITING",
      "phase": [
        "NA"
      ],
      "conditions": [
        "Solid Cancer",
        "Non-Small Cell Lung Cancer",
        "Melanoma"
      ],
      "interventions": [
        "Urolithin A",
        "Placebo",
        "Bio specimens"
      ],
      "sponsor": "Goethe University",
      "enrollment": 45,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT07250477",
      "title": "Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer",
      "brief_title": "Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer Stage IIIC",
        "Non-small Cell Lung Cancer Stage IV",
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        "Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment.",
        "Standard of Care"
      ],
      "sponsor": "University of California, Davis",
      "enrollment": 56,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='untreated'"
      ]
    },
    {
      "nct_id": "NCT07264647",
      "title": "Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)",
      "brief_title": "Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)",
      "status": "RECRUITING",
      "phase": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III NSCLC"
      ],
      "interventions": [
        "Tislelizumab",
        "surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines",
        "Chemoradiotherapy"
      ],
      "sponsor": "Fondazione Ricerca Traslazionale",
      "enrollment": 30,
      "start_date": null,
      "primary_completion_date": null,
      "locations_count": null,
      "study_type": "",
      "found_by_queries": [
        "cond='non-small cell lung cancer', kw='non-smoker'"
      ]
    }
  ],
  "agent_reasoning": "The patient's clinical profile—a **43-year-old female, never smoker, with signet-ring cell lung adenocarcinoma**—is highly characteristic of a subtype of non-small cell lung cancer (NSCLC) driven by specific oncogenic rearrangements. In particular, **signet-ring cell histology** in lung adenocarcinoma has a very high correlation (up to 90% in some series) with **ALK (Anaplastic Lymphoma Kinase) rearrangements**. Given the CT findings of bilateral lung involvement and pleural effusion, the disease is likely Stage IV (metastatic).\n\nSince the patient is treatment-naive, the immediate priority is molecular profiling (ALK, ROS1, RET, EGFR, etc.). Below are the most relevant clinical trial opportunities based on her predicted biomarkers and clinical phenotype.\n\n### 1. ALK-Specific Trials (High Probability Fit)\nGiven the histology and \"never smoker\" status, these trials are the most likely to be applicable once molecular testing confirms an ALK rearrangement.\n\n*   **Lorlatinib as First-line Treatment (NCT06092086)**\n    *   **Focus:** Evaluates Lorlatinib (a 3rd-generation ALK TKI) as the initial systemic therapy for advanced ALK+ NSCLC.\n    *   **Relevance:** High. This is a potential first-line option for this patient if ALK positivity is confirmed.\n*   **Brigatinib + Local Ablative Treatment (NCT06620835)**\n    *   **Focus:** Investigates the optimization of local treatments (like radiation) alongside Brigatinib in ALK-rearranged NSCLC.\n    *   **Relevance:** Relevant for patients with advanced disease to improve local control.\n*   **Ensartinib Adjuvant/Advanced Study (NCT05241028 / NCT04322890)**\n    *   **Focus:** Various trials investigating Ensartinib or Alectinib in ALK+ populations.\n\n### 2. ROS1/RET/NTRK (Targeted Therapy)\nIf the patient tests negative for ALK, other driver mutations common in young non-smokers (ROS1, RET) should be targeted.\n\n*   **Repotrectinib for ALK, ROS1, or NTRK1-3 Rearrangements (NCT03093116)**\n    *   **Focus:** A Phase 1/2 study of a next-generation TKI designed to be more potent and cross the blood-brain barrier.\n    *   **Relevance:** Excellent \"umbrella\" option if any of these fusions are detected.\n*   **RET-Inhibitor Studies (NCT06147570, NCT06031558)**\n    *   **Focus:** Specific inhibitors for RET fusion-positive patients (another common driver in this demographic).\n\n### 3. Phenotype-Specific (Never Smokers)\nThese trials target the specific clinical characteristics of the patient rather than a specific gene, or require any \"actionable mutation.\"\n\n*   **LP-300 with Carboplatin and Pemetrexed (NCT05456256)**\n    *   **Focus:** Specifically for **never smokers** with advanced lung adenocarcinoma and actionable genomic alterations.\n    *   **Status:** Typically requires prior treatment with a TKI (second-line), but highly relevant if the patient progresses on initial targeted therapy.\n*   **Sacituzumab Tirumotecan (MK-2870) vs. Chemotherapy (NCT06074588)**\n    *   **Focus:** An antibody-drug conjugate (ADC) for patients with \"genomic alterations\" who have been previously treated.\n\n### 4. General Stage IV Adenocarcinoma (First-Line)\nIf molecular testing is negative or pending, the patient may be eligible for trials combining standard chemotherapy with immunotherapy or novel agents.\n\n*   **Carboplatin + Pemetrexed + Bevacizumab +/- Atezolizumab (NCT03786692)**\n    *   **Focus:** A Phase 2 trial for Stage IV NSCLC using the \"standard of care\" backbone for adenocarcinoma (Pemetrexed/Carboplatin) with or without immunotherapy.\n\n### Clinical Caveats & Recommendations\n*   **Molecular Testing:** The patient must undergo FISH or NGS testing for ALK, ROS1, RET, and EGFR immediately. The presence of signet-ring cells is a \"pathological red flag\" for ALK.\n*   **Performance Status:** Most trials require an ECOG status of 0-1 (fully active or restricted in physically strenuous activity but ambulatory).\n*   **Brain Metastases:** Given her symptoms and histology, brain imaging (MRI) is essential, as ALK+ and ROS1+ cancers have a high propensity for CNS involvement. Many trials (like **NCT06315010**) specifically recruit patients with brain metastases.",
  "tool_call_trace": [
    {
      "call_index": 0,
      "tool_name": "normalize_medical_terms",
      "args": {
        "term_type": "condition",
        "raw_term": "Lung adenocarcinoma with signet-ring cell features"
      },
      "result_summary": "MedGemma normalized 'Lung adenocarcinoma with signet-ring cell features' (condition): variants=['Lung adenocarcinoma with signet-ring cell features'], latency 25341ms",
      "result_count": 0,
      "latency_ms": 25346.53770807199,
      "error": null
    },
    {
      "call_index": 1,
      "tool_name": "normalize_medical_terms",
      "args": {
        "term_type": "phenotype",
        "patient_context": "43yo female, never smoker, lung adenocarcinoma with signet-ring cells",
        "raw_term": "never smoker"
      },
      "result_summary": "MedGemma normalized 'never smoker' (phenotype): variants=['never smoker'], latency 25596ms",
      "result_count": 0,
      "latency_ms": 25600.80920800101,
      "error": null
    },
    {
      "call_index": 2,
      "tool_name": "normalize_medical_terms",
      "args": {
        "patient_context": "43yo female, lung adenocarcinoma with signet-ring cells, never smoker",
        "raw_term": "ALK rearrangement",
        "term_type": "biomarker"
      },
      "result_summary": "MedGemma normalized 'ALK rearrangement' (biomarker): variants=['ALK rearrangement'], latency 25877ms",
      "result_count": 0,
      "latency_ms": 25903.191791963764,
      "error": null
    },
    {
      "call_index": 3,
      "tool_name": "search_trials",
      "args": {
        "eligibility_keywords": "signet-ring",
        "condition": "non-small cell lung cancer"
      },
      "result_summary": "Found 0 trials (API total: 0), latency 174ms. NCT IDs: []",
      "result_count": 0,
      "latency_ms": 174.50891702901572,
      "error": null
    },
    {
      "call_index": 4,
      "tool_name": "search_trials",
      "args": {
        "eligibility_keywords": "never smoker",
        "condition": "non-small cell lung cancer"
      },
      "result_summary": "Found 5 trials (API total: 5), latency 1493ms. NCT IDs: ['NCT05456256', 'NCT06196424', 'NCT00301119', 'NCT03786692', 'NCT06800586']",
      "result_count": 5,
      "latency_ms": 1494.3778329761699,
      "error": null
    },
    {
      "call_index": 5,
      "tool_name": "search_trials",
      "args": {
        "eligibility_keywords": "ALK rearrangement",
        "condition": "non-small cell lung cancer"
      },
      "result_summary": "Found 12 trials (API total: 12), latency 1499ms. NCT IDs: ['NCT05236946', 'NCT06620835', 'NCT06234579', 'NCT05724004', 'NCT06074588', 'NCT06092086', 'NCT03093116', 'NCT06528847', 'NCT05122806', 'NCT07140016', 'NCT05014464', 'NCT04084717']",
      "result_count": 12,
      "latency_ms": 1501.2784170685336,
      "error": null
    },
    {
      "call_index": 6,
      "tool_name": "search_trials",
      "args": {
        "condition": "non-small cell lung cancer",
        "eligibility_keywords": "ROS1 rearrangement"
      },
      "result_summary": "Found 3 trials (API total: 3), latency 1480ms. NCT IDs: ['NCT06315010', 'NCT03093116', 'NCT04084717']",
      "result_count": 3,
      "latency_ms": 1480.9529579943046,
      "error": null
    },
    {
      "call_index": 7,
      "tool_name": "search_trials",
      "args": {
        "condition": "non-small cell lung cancer",
        "eligibility_keywords": "RET fusion"
      },
      "result_summary": "Found 11 trials (API total: 11), latency 1568ms. NCT IDs: ['NCT07330596', 'NCT04777175', 'NCT04900935', 'NCT06196424', 'NCT06147570', 'NCT04322890', 'NCT06109558', 'NCT06031558', 'NCT06074588', 'NCT06563999', 'NCT01639508']",
      "result_count": 11,
      "latency_ms": 1569.1658750874922,
      "error": null
    },
    {
      "call_index": 8,
      "tool_name": "search_trials",
      "args": {
        "condition": "Adenocarcinoma",
        "eligibility_keywords": "signet-ring"
      },
      "result_summary": "Found 2 trials (API total: 2), latency 311ms. NCT IDs: ['NCT04716257', 'NCT01717924']",
      "result_count": 2,
      "latency_ms": 311.16066593676805,
      "error": null
    },
    {
      "call_index": 9,
      "tool_name": "search_trials",
      "args": {
        "eligibility_keywords": "untreated",
        "condition": "non-small cell lung cancer"
      },
      "result_summary": "Found 20 trials (API total: 20), latency 1396ms. NCT IDs: ['NCT05276726', 'NCT05602259', 'NCT06501378', 'NCT04701476', 'NCT07020221', 'NCT06939595', 'NCT05522660', 'NCT04302025', 'NCT07250477', 'NCT07161310', 'NCT06248606', 'NCT05229614', 'NCT05789082', 'NCT05973773', 'NCT06946797', 'NCT06581419', 'NCT05742607', 'NCT06735391', 'NCT05098132', 'NCT06875310']",
      "result_count": 20,
      "latency_ms": 1396.371667040512,
      "error": null
    },
    {
      "call_index": 10,
      "tool_name": "search_trials",
      "args": {
        "eligibility_keywords": "ALK fusion",
        "condition": "non-small cell lung cancer"
      },
      "result_summary": "Found 17 trials (API total: 17), latency 1432ms. NCT IDs: ['NCT07330596', 'NCT04777175', 'NCT04900935', 'NCT06361589', 'NCT06196424', 'NCT05284539', 'NCT05241028', 'NCT01994057', 'NCT04322890', 'NCT05487391', 'NCT06074588', 'NCT04087473', 'NCT06563999', 'NCT04777084', 'NCT05122806', 'NCT05950139', 'NCT05014464']",
      "result_count": 17,
      "latency_ms": 1432.4756249552593,
      "error": null
    },
    {
      "call_index": 11,
      "tool_name": "search_trials",
      "args": {
        "condition": "non-small cell lung cancer",
        "eligibility_keywords": "non-smoker"
      },
      "result_summary": "Found 11 trials (API total: 11), latency 1527ms. NCT IDs: ['NCT05456256', 'NCT06196424', 'NCT07099027', 'NCT03199651', 'NCT00301119', 'NCT07264647', 'NCT03786692', 'NCT06068049', 'NCT03774758', 'NCT06156527', 'NCT06800586']",
      "result_count": 11,
      "latency_ms": 1527.6489579118788,
      "error": null
    },
    {
      "call_index": 12,
      "tool_name": "get_trial_details",
      "args": {
        "nct_id": "NCT05456256"
      },
      "result_summary": "Fetched details for NCT05456256 (A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma), latency 1452ms",
      "result_count": 0,
      "latency_ms": 1454.1705419542268,
      "error": null
    }
  ],
  "total_api_calls": 13,
  "total_unique_nct_ids": 63,
  "gemini_input_tokens": 53079,
  "gemini_output_tokens": 1695,
  "gemini_estimated_cost": 0.08329875,
  "medgemma_calls": 3,
  "medgemma_estimated_cost": 0.06877,
  "latency_ms": 125211.05200005695
}